NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
11.57
-0.15 (-1.28%)
Nov 13, 2026, 1:09 PM EST - Market open
NovoCure Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 725.39 | 655.35 | 605.22 | 509.34 | 537.84 | 535.03 | |
Revenue Growth | 12.94% | 8.28% | 18.82% | -5.30% | 0.53% | 8.23% |
Cost of Revenue | 165.01 | 165.17 | 136.18 | 127.54 | 114.26 | 114.24 |
Gross Profit | 560.38 | 490.18 | 469.05 | 381.8 | 423.58 | 420.79 |
Selling, General & Admin | 450.63 | 413.93 | 427.21 | 386.97 | 306.41 | 263.18 |
Research & Development | 228.79 | 224.54 | 209.37 | 220.99 | 206.09 | 201.3 |
Operating Expenses | 679.41 | 638.47 | 636.58 | 607.96 | 512.5 | 464.49 |
Operating Income | -119.04 | -148.29 | -167.54 | -226.16 | -88.91 | -43.69 |
Interest Expense | -27.71 | -17.04 | -11.49 | -3.32 | -3.33 | -3.44 |
Interest & Investment Income | - | 12.87 | 22.72 | 19.64 | 10.96 | 0.79 |
Currency Exchange Gain (Loss) | -4.32 | -4.32 | -0.72 | -0.8 | -3.52 | -4.03 |
Other Non Operating Income (Expenses) | -0.86 | -0.86 | -0.6 | -0.79 | -1.26 | -1.37 |
EBT Excluding Unusual Items | -151.93 | -157.63 | -157.62 | -211.42 | -86.06 | -51.74 |
Merger & Restructuring Charges | -2.2 | -2.2 | -2 | -6.23 | - | - |
Gain (Loss) on Sale of Investments | 26.89 | 26.89 | 28.27 | 26.4 | 4.83 | 0.31 |
Asset Writedown | -3.31 | -3.31 | -0.95 | -0.48 | -0.61 | -0.64 |
Other Unusual Items | - | - | 1.14 | - | - | - |
Pretax Income | -130.54 | -136.25 | -131.16 | -191.74 | -81.85 | -52.08 |
Income Tax Expense | -8.81 | -0.02 | 37.47 | 15.3 | 10.69 | 6.28 |
Net Income | -121.73 | -136.23 | -168.63 | -207.04 | -92.53 | -58.35 |
Net Income to Common | -121.73 | -136.23 | -168.63 | -207.04 | -92.53 | -58.35 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 115 | 111 | 108 | 106 | 105 | 103 |
Shares Outstanding (Diluted) | 115 | 111 | 108 | 106 | 105 | 103 |
Shares Change | 3.86% | 3.37% | 1.36% | 1.65% | 1.19% | -5.00% |
EPS (Basic) | -1.06 | -1.22 | -1.56 | -1.95 | -0.88 | -0.56 |
EPS (Diluted) | -1.06 | -1.22 | -1.56 | -1.95 | -0.88 | -0.56 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -24.61 | -75.68 | -69.22 | -100.43 | 9.43 | 58.59 |
Free Cash Flow Per Share | -0.21 | -0.68 | -0.64 | -0.94 | 0.09 | 0.57 |
Gross Margin | 77.25% | 74.80% | 77.50% | 74.96% | 78.76% | 78.65% |
Operating Margin | -16.41% | -22.63% | -27.68% | -44.40% | -16.53% | -8.17% |
Profit Margin | -16.78% | -20.79% | -27.86% | -40.65% | -17.21% | -10.91% |
Free Cash Flow Margin | -3.39% | -11.55% | -11.44% | -19.72% | 1.75% | 10.95% |
EBITDA | -103.49 | -135.16 | -157.67 | -216.46 | -79.34 | -34.53 |
EBITDA Margin | -14.27% | -20.62% | -26.05% | -42.50% | -14.75% | -6.45% |
D&A For EBITDA | 15.55 | 13.13 | 9.87 | 9.7 | 9.57 | 9.17 |
EBIT | -119.04 | -148.29 | -167.54 | -226.16 | -88.91 | -43.69 |
EBIT Margin | -16.41% | -22.63% | -27.68% | -44.40% | -16.53% | -8.17% |